This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies.Continue
Every patient prescribed Pradaxa will receive a Patient Alert Card in the medication pack. As the card contains important information the patient should be instructed to carry the patient alert card at all times and present it when seeing a health care professional. The patient should be counselled about the need for compliance and signs of bleeding and when to seek medical attention.
This risk minimisation material provides recommendations for the use of Pradaxa in NVAF and DVT/PE in order to minimise the risk of bleeding. Please ensure that you are familiar with this material as it contains important safety information. In particular it is aimed at increasing awareness about the potential risk of bleeding during treatment with Pradaxa and providing guidance on how to manage that risk.
For hard copies please contact our medical information department at 01344 424600 or email: medinfo@bra.boehringer-ingelheim.com
If you would like to make a comment or send us feedback on this material, click here.
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine.
This PIL is in PDF format and so you must have a PDF reader installed on your device to read it.
Boehringer Ingelheim Limited
http://www.boehringer-ingelheim.co.uk
Address : Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS
Telephone : +44 (0)1344 424 600
Fax : +44 (0)1344 741 298
Medical Information Direct Line : +44 (0)1344 742579 - Pradaxa enquiries
Medical Information e-mail : medinfo@bra.boehringer-ingelheim.com
Legal categories
Active ingredients/generics
Summaries of Product Characteristics (SPCs):